Focus on Diabetes Care

Back to articles

Data support cardiovascular benefits with canagliflozin


Use of canagliflozin (Invokana—Janssen) in patients with type 2 diabetes who had established cardiovascular (CV) disease or CV risk factors resulted in a 14% reduction in the composite endpoint of risk of death from CV causes, nonfatal myocardial infarction (MI), or nonfatal stroke but was associated with an increased risk of amputation, according to results of two clinical trials from the CANVAS (Canagliflozin Cardiovascular Assessment Study) program.


Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;[Epub ahead of print].